{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:14:49Z","timestamp":1785460489384,"version":"3.56.0"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T00:00:00Z","timestamp":1461196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0153895","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T18:08:47Z","timestamp":1461262127000},"page":"e0153895","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4"],"prefix":"10.1371","volume":"11","author":[{"given":"Hanan H.","family":"Rizk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia M.","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia L.","family":"Al-Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala O.","family":"El-Mesallamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,4,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-132-4-200002150-00008","article-title":"Pathogenesis, natural history, treatment, and prevention of hepatitis C","volume":"132","author":"TJ Liang","year":"2000","journal-title":"Annals of internal medicine"},{"key":"ref2","unstructured":"World Health Organization. Hepatitis C. WHO fact sheet 164. 2015. Available:<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/<\/ext-link>"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"14757","DOI":"10.1073\/pnas.1008877107","article-title":"Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt","volume":"107","author":"FD Miller","year":"2010","journal-title":"PNAS"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jvh.12247","article-title":"Historical epidemiology of hepatitis C virus (HCV) in selected countries","volume":"1","author":"P Bruggmann","year":"2014","journal-title":"J viral hepatitis"},{"key":"ref5","unstructured":"Center for Disease Analysis. CDA 2014. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.centerforda.com\/factfiles\/Fact%20Sheets_Egypt.pdf\" xlink:type=\"simple\">http:\/\/www.centerforda.com\/factfiles\/Fact%20Sheets_Egypt.pdf<\/ext-link>"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1136\/bmj.g3308","article-title":"Antiviral treatment of hepatitis C","volume":"348","author":"ER Feeney","year":"2014","journal-title":"Bmj"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4254\/wjh.v7.i5.725","article-title":"Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade","volume":"7","author":"H Barth","year":"2015","journal-title":"World J Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jhep.2014.05.001","article-title":"EASL recommendations on treatment of hepatitis C 2014","volume":"61","year":"2014","journal-title":"J hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"SJ Hadziyannis","year":"2004","journal-title":"Ann. Intern. Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"MG Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e0121395","DOI":"10.1371\/journal.pone.0121395","article-title":"IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C","volume":"10","author":"E Estrabaud","year":"2015","journal-title":"Plos One"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"267483","DOI":"10.1155\/2012\/267483","article-title":"Hepatitis C variability, patterns of resistance, and impact on therapy","volume":"2012","author":"CS Strahotin","year":"2012","journal-title":"Adv Virol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/hep.24683","article-title":"Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4","volume":"55","author":"S De Nicola","year":"2012","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"A Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.1016\/S0168-8278(12)61209-4","article-title":"Insulin Resistance Undermines the Advantages of Il28b Polymorphism in the Pegylated Interferon Alpha 2b and Ribavirin Treatment for Chronic Hepatitis C Patients with Genotype 1","volume":"56","author":"E Ogawa","year":"2012","journal-title":"J hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/jir.2013.0115","article-title":"IL28B rs 12979860 predicts response to treatment in Egyptian hepatitis C virus genotype 4 patients and alpha fetoprotein increases its predictive strength","volume":"34","author":"SS Youssef","year":"2014","journal-title":"J Interferon Cytokine Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy","volume":"94","author":"AM Intlekofer","year":"2013","journal-title":"J. Leukoc. Biol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3892\/br.2014.217","article-title":"Expression levels of CD28, CTLA-4, PD-1 and Tim-3 as novel indicators of T-cell immune function in patients with chronic hepatitis B virus infection","volume":"2","author":"L Wang","year":"2014","journal-title":"Biomed Rep"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/art.27417","article-title":"Lower expression levels of the programmed death 1 receptor on CD4+CD25+ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus","volume":"62","author":"H Kristjansdottir","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2796.2007.01879.x","article-title":"Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis","volume":"263","author":"XB Wang","year":"2008","journal-title":"J. Intern. Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1478-3231.2011.02694.x","article-title":"Correlations of CTLA-4 gene polymorphisms and hepatitis C chronic infection","volume":"32","author":"DL Danilovic","year":"2012","journal-title":"Liver"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1086\/374561","article-title":"Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection","volume":"187","author":"LJ Yee","year":"2003","journal-title":"J. Infect. Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jhep.2012.01.011","article-title":"A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping","volume":"56","author":"JR Vidal-Castineira","year":"2012","journal-title":"J hepatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"DR Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"ref25","first-page":"545","article-title":"Progress toward prevention and control of hepatitis C virus infection\u2013Egypt, 2001\u20132012","volume":"61","year":"2012","journal-title":"Morb Mortal Wkly Rep"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1478-3231.2010.02411.x","article-title":"New direct-acting antivirals&apos; combination for the treatment of chronic hepatitis C","volume":"31","author":"T Asselah","year":"2011","journal-title":"Liver Int"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"Recommendations on Treatment of Hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e55285","DOI":"10.1371\/journal.pone.0055285","article-title":"Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting","volume":"8","author":"B Maasoumy","year":"2013","journal-title":"Plos One"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"E Poveda","year":"2014","journal-title":"Antiviral Res"},{"key":"ref30","unstructured":"Aggour S. FY 2015\/2016 state budget announced, analysts weigh in Daily News Egypt. 2015. Available:<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.dailynewsegypt.com\/2015\/03\/26\/3-of-gdp-in-20162017-budget-to-go-to-health-6-to-education-dimian\/\" xlink:type=\"simple\">http:\/\/www.dailynewsegypt.com\/2015\/03\/26\/3-of-gdp-in-20162017-budget-to-go-to-health-6-to-education-dimian\/<\/ext-link>."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1016\/S2214-109X(14)70365-1","article-title":"Hepatitis C drug affordability","volume":"3","author":"M Kamal-Yanni","year":"2015","journal-title":"Lancet Glob Health"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apm.12377","article-title":"A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients","volume":"123","author":"D El Sabaawy","year":"2015","journal-title":"APMIS"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1089\/jir.2013.0127","article-title":"The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C. J Interferon Cytokine Res: the official journal of the","volume":"34","author":"H Shehab","year":"2014","journal-title":"International Society for Interferon and Cytokine Research"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.2471\/BLT.11.097147","article-title":"Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis","volume":"90","author":"N Ford","year":"2012","journal-title":"B World Health Organ"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"MW Fried","year":"2002","journal-title":"New Engl J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nrgastro.2012.101","article-title":"Genetics of IL28B and HCV-response to infection and treatment","volume":"9","author":"CN Hayes","year":"2012","journal-title":"Nat Rev Gastro Hepat"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e10509","DOI":"10.5812\/hepatmon.10509","article-title":"The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis","volume":"13","author":"M Khairy","year":"2013","journal-title":"Hepat Mon"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4254\/wjh.v5.i4.182","article-title":"Platelet count and sustained virological response in hepatitis C treatment","volume":"5","author":"T Kanda","year":"2013","journal-title":"World J Hepatol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e2391","DOI":"10.1371\/journal.pone.0002391","article-title":"Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype","volume":"3","author":"H Abdoul","year":"2008","journal-title":"PLoS ONE"},{"key":"ref40","article-title":"\u03b1-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response","author":"Y Tachi","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"ref41","first-page":"10","article-title":"The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin","volume":"7","author":"ZM Younossi","year":"2012","journal-title":"J Transl Med"},{"key":"ref42","doi-asserted-by":"crossref","DOI":"10.1186\/gm273","article-title":"Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort","volume":"3","author":"KR Smith","year":"2011","journal-title":"Genome Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e20904","DOI":"10.1371\/journal.pone.0020904","article-title":"An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C","volume":"6","author":"TR O'Brien","year":"2011","journal-title":"Plos One"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.immunol.20.091101.091806","article-title":"The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses","volume":"20","author":"BM Carreno","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ana.20514","article-title":"A PD-1 polymorphism is associated with disease progression in multiple sclerosis","volume":"58","author":"A Kroner","year":"2005","journal-title":"Ann Neurol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00393-014-1415-y","article-title":"Meta-analysis of genetic polymorphisms in programmed cell death 1: Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility","volume":"74","author":"YH Lee","year":"2014","journal-title":"Z Rheumatol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2265.2007.02848.x","article-title":"Tag SNP screening of the PDCD1 gene for association with Graves&apos; disease","volume":"67","author":"PR Newby","year":"2007","journal-title":"Clin Endocrinol"},{"key":"ref48","first-page":"56","article-title":"The CTLA4-819 C\/T Dimorphism Is Associated with Type 1 Diabetes in Egyptian Children","volume":"38","author":"HM Saleh","year":"2009","journal-title":"Iran J Public Health"},{"key":"ref49","first-page":"11","article-title":"Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV","volume":"17","author":"M Matas","year":"2014","journal-title":"Int. Microbiol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"11398","DOI":"10.1128\/JVI.01177-06","article-title":"PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion","volume":"80","author":"S Urbani","year":"2006","journal-title":"J Virol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1086\/374561","article-title":"Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection","volume":"187","author":"LJ Yee","year":"2003","journal-title":"J. Infect. Dis"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e93011","DOI":"10.1371\/journal.pone.0093011","article-title":"IL28B Polymorphisms and Clinical Implications for Hepatitis C Virus Infection in Uzbekistan","volume":"9","author":"D Khudayberganova","year":"2014","journal-title":"Plos One"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"e15076","DOI":"10.5812\/hepatmon.15076","article-title":"The IFN-lambda Genetic Polymorphism Association With the Viral Clearance Induced by Hepatitis C Virus Treatment in Pakistani Patients","volume":"14","author":"I Tipu","year":"2014","journal-title":"Hepatitis monthly"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0153895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T22:56:50Z","timestamp":1567810610000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0153895"}},"subtitle":[],"editor":[{"given":"Ming-Lung","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,4,21]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0153895","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,21]]}}}